Apple-simple, Google-smart
GPS + Autopilot
For drug development
Mission
Shorten clinical trials, save lives sooner
Technology
Simple interface with smart analytics
Problem: Clinical Trial Inefficiency
$40–70B Yearly Spend
on decade-long trials
$41k Per Patient Cost
in Phase 3 oncology studies (↑ 40–60% since 2021)
30–70% Avoidable Waste
from static designs and manual data processing
Cost per patient: https://www.jpmorgan.com/content/dam/jpm/global/en/innovation/economics-of-clinical-development-2024.pdf
Waste estimate source (Tufts CSDD brief): https://csdd.tufts.edu/wp-content/uploads/2023/10/TuftsCSDD_CostDriversBrief_2023.pdf
2
Solution — "Self-Driving" Trials
Big-Tech Pattern
Google Search indexes everything
Tesla Autopilot learns continuously
Netflix A/B uses synthetic controls
Pulser Analogue
Secure EMR plug-ins stream real-time patient data
Adaptive AI drops/adds/resizes arms
Synthetic placebo arm (historic twins)
Impact!
10× richer dataset
–50% timeline
Treat 100% of volunteers
3
Pulser Flywheel
Data Moat
Every new trial enlarges the EMR graph
Learning Loop
Models sharpen with each pass
Network Effects
Hospitals earn revenue, sponsors gain speed, patients access therapy
= 70% cost reduction / 50% time savings
4
Market & Business Model
"Bigger than Uber's launch TAM, priced like Salesforce."
$70B
TAM today
US CDM/CRO spend
$80B+
TAM 2032
Gene/mRNA boom
35%
Top Pricing
Of CDM budget + 5–8% royalty/equity
$100M
Revenue goal
ARR within 18 months
5
Traction & Roadmap: 2024-2027
Our implementation strategy follows these key milestones:
2024
Sandbox trial in 1-hospital virtual campus ✓
2025
2-4 paid adaptive trials kick off
2026
Reusable synthetic-control library released
2027
Cash-flow breakeven; open to CRO partners
Each milestone builds on proven success, creating a sustainable growth trajectory toward market leadership.
6
Elite Team: DARPA Expertise, Clinical Excellence
Our team combines DARPA-grade mathematical expertise with Bristol-Myers Squibb-level clinical execution:
Dr. Jeffrey Galpin MD
Founder / CEO & CMO
PI on first NIH-approved U.S. gene-therapy trial; 300+ studies across HIV, HBV/HCV, oncology, immunology.
There was an error generating this image
Dr. Kirstie Bellman PhD
Co-Founder · Chief Analytics
30 yrs DARPA/Aerospace AI, founded Aerospace Integration Center, NIH informatics adviser.
Dr. Christopher Landauer PhD
Co-Founder · Adv. Math & NLP
Caltech mathematician, 150+ papers; DoD/CIA pattern-analysis systems.
Michael Stevens PharmD
Co-Founder · Clinical Trial Research Officer
Ex-VP Virology, Bristol-Myers Squibb; designed >50 FDA viral trials.
7
Team (continued)
Ken Maranga JD
Co-Founder · Chief Strategic (Legal & Biz)
40 yrs med-mal & life-science litigation, ex-White Memorial Medical Center.
Bradley Burnam
Chief Business Officer
CEO Turn Therapeutics; marketing, manufacturing & financing expert.
Dr. Brian D. Athey PhD
Senior Consultant · Computational/ Bio-informatics
Chair, UMich Dept. of Computational Medicine & Bioinformatics.
Dipak Reddy BS CIS
Chief Information Officer
20 yrs hospital IT & HIPAA/CMMC Cybersecurity.
8
Seed / Bridge Round – US $2-4 M (Ask)
Use mid-point US $3.5 M for the allocation.
≈ 15 months runway to 3 paid trials + FDA dossier.
R&D: 47%
US $1.65 M allocation from mid-point US $3.5 M
Payroll (non-R&D): 27%
US $0.95 M allocation from mid-point US $3.5 M
G&A: 20%
US $0.70 M allocation from mid-point US $3.5 M
Sales & Mktg: 6%
US $0.20 M allocation from mid-point US $3.5 M
9
Scale-Up Plan – Total US $10 M
Our strategic growth roadmap outlines how funding will be deployed to achieve key milestones over the next three years.
Year 1 Seed
US $3.5 M
-Complete platform development
-Launch initial pilot programs
-Establish proof of concept
Years 2-3 Scale
≤ US $6.5 M
-SaaS roll-out to market
-Secure 4 new patents
-Scale to 20+ concurrent trials
Future Growth
Expansion potential
-International market entry
-Additional product verticals
-Strategic partnerships
10
Competitive Heat Map & Why Now
The healthcare AI and clinical trial landscape is evolving rapidly, with significant advantages for Pulser's approach.
Market Leaders & Pulser's Edge:
Why Now:
Market Conditions Are Ideal
Massive VC Investment
VC poured US $6.7B into biopharma platforms Q1 2025
Regulatory Support
FDA Adaptive Designs Guidance (2019) unlocked AI-driven methods
Hospital Revenue Needs
Hospitals hunting CRO-style
revenue streams
Pulser turns drug development from a marathon into a sprint.
11
June 12th 2025